LBBW VC

LBBW Venture Capital GmbH is the investment arm of Landesbank Baden-Württemberg, established in 1998 and located in Stuttgart, Germany. The firm specializes in financing early to late-stage growth companies, particularly in the sectors of industrial technologies, information technology, software, telecommunications, innovative services, and life sciences. LBBW VC primarily targets investments in Southern Germany but is open to opportunities throughout Germany, Austria, and Switzerland. It typically invests between €0.5 million and €1.5 million per company, with the potential to contribute up to €5 million across multiple financing rounds. The firm takes an active role in its investments, often seeking advisory or supervisory board positions for larger stakes. LBBW VC has a strong international track record, having invested in over 60 companies, and typically exits investments within two to five years through trade sales or initial public offerings. The team boasts a history that includes two IPOs and the backing of one unicorn.

Julian Hebler

Investment Manager

39 past transactions

specter automation

Seed Round in 2025
Specter Automation specializes in providing web-based construction management software designed to address the inefficiencies within the construction sector, which remains significantly under-digitized. By harnessing artificial intelligence, the company offers a three-dimensional lookahead platform that enables construction firms, including small and midsize enterprises, to effectively utilize existing digital planning data from the pre-construction phase directly on site. This integration facilitates improved communication among all stakeholders, highlights inefficiencies, and identifies potential planning errors, ultimately streamlining construction processes. By reducing the organizational effort involved in construction management, Specter Automation's software significantly decreases the likelihood of construction delays, thereby enhancing overall project efficiency and productivity.

Metergrid

Seed Round in 2025
Metergrid is a developer of software solutions focused on decentralized energy systems, specifically tailored for the housing industry and local energy suppliers. Founded in 2021, the company aims to support the 1.5-degree climate target for 44 million residents of multi-family homes in Germany. Metergrid provides a comprehensive automated cloud solution that facilitates the management, realization, and billing of tenant electricity projects and charging infrastructures. Their services encompass profitability calculations, project implementation, and the provision of billing software and hardware solutions. By enabling property owners to supply tenants with clean, locally generated photovoltaic electricity, Metergrid combines environmental sustainability with reduced energy costs and attractive returns for property owners and system operators. The company is committed to advancing a decentralized and sustainable energy future.

Leon Nanodrugs

Series D in 2024
Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Impossible Cloud

Funding Round in 2024
Impossible Cloud is a decentralized cloud platform that leverages web3 technology to deliver enterprise-grade multi-service cloud solutions for businesses. By offering faster, more affordable, and secure services than traditional hyperscalers and private clouds, it aims to transform the cloud computing landscape. The platform is designed to provide unlimited storage capacity with no hidden costs, ensuring 100% durability and availability. With a focus on B2B customers, Impossible Cloud operates on a fiat-based payment system, allowing businesses to engage without the complexities associated with tokens or cryptocurrencies. Its decentralized architecture enhances performance and efficiency by connecting users to a global network of storage hubs, facilitating effective data management for various needs, including big data, backups, and archives.

AIPERIA

Series A in 2024
AIPERIA is a German-based software as a service (SaaS) company that specializes in sustainable demand planning for fresh food. The company has developed an artificial intelligence-driven platform that facilitates comprehensive planning from food production to supermarket shelves. By enabling suppliers to accurately forecast demand, AIPERIA ensures that only the necessary quantities of fresh food are produced and delivered to retailers. This approach not only enhances efficiency in the supply chain but also promotes sustainability in food retail by minimizing waste and optimizing resource use.

Threedy

Series A in 2024
Threedy GmbH, founded in 2020 and based in Darmstadt, Germany, specializes in providing the instant3Dhub platform, which supports high-performance visual computing for various industries, including automotive, aerospace, and energy. This cloud-native platform facilitates the visualization of large data sets and enables the development of responsive and interactive 3D applications. Key features of instant3Dhub include a 3D streaming architecture, integrated 3D Spaces for contextual sharing, and a unified application programming interface that connects business data and sensors. By leveraging 3D data models, Threedy aims to drive digital innovation in products, services, and business processes, ultimately simplifying operations and reducing costs for its clients.

BLUU Seafood

Series A in 2023
Bluu Seafood is a biotechnology company focused on the development and commercial production of cultivated seafood derived from fish cells. The company aims to provide healthier and more sustainable alternatives to traditional seafood, ensuring that its products are both nutritious and environmentally friendly. By utilizing innovative food technology, Bluu Seafood seeks to deliver fish products that do not harm animals or contribute to the depletion of fragile ocean ecosystems, aligning with growing consumer demand for responsible food sources. This approach allows Bluu Seafood to cater to customers seeking sustainable seafood options while promoting a more ethical food industry.

Oska Health

Pre Seed Round in 2023
Oska Health provides digital-enabled care solutions specifically for patients with chronic kidney disease, addressing a significant need within the healthcare sector. The company employs evidence-based medical practices and behavioral science to empower individuals, aiming to reduce the risks of cardiovascular complications and kidney failure while lowering overall care costs. Oska Health collaborates with healthcare payers to offer a holistic solution that includes a personalized coach, an advanced health application, and intelligent treatment plan algorithms. This comprehensive approach addresses the physical, emotional, and social needs of patients, fostering the establishment of new health routines and ultimately promoting better health outcomes while minimizing complications and hospitalizations.

specter automation

Seed Round in 2023
Specter Automation specializes in providing web-based construction management software designed to address the inefficiencies within the construction sector, which remains significantly under-digitized. By harnessing artificial intelligence, the company offers a three-dimensional lookahead platform that enables construction firms, including small and midsize enterprises, to effectively utilize existing digital planning data from the pre-construction phase directly on site. This integration facilitates improved communication among all stakeholders, highlights inefficiencies, and identifies potential planning errors, ultimately streamlining construction processes. By reducing the organizational effort involved in construction management, Specter Automation's software significantly decreases the likelihood of construction delays, thereby enhancing overall project efficiency and productivity.

Code Intelligence

Series A in 2022
Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in security software aimed at helping developers identify and address vulnerabilities in their code. The company offers an automated application security testing platform that utilizes coverage-based fuzzing and symbolic code execution to generate attack inputs, thereby facilitating the detection of critical vulnerabilities and crashes. This solution significantly reduces the need for extensive expert knowledge by establishing a continuous testing infrastructure. Code Intelligence serves a diverse clientele, including notable organizations such as Bosch, Deutsche Börse Group, and Deutsche Telekom, ensuring that their software remains secure and reliable.

Cedalo

Seed Round in 2022
Cedalo is a software startup focused on empowering individuals, including those without programming skills, to create and manage applications and microservices for the Internet of Things (IoT). The company has developed a no-code platform that facilitates the building of real-time stream processing applications. This platform provides users with tools for visualization, analysis, simulation, and control of IoT devices, enabling them to process and analyze data in real time. By prioritizing intuitive operation and a user-friendly modeling environment, Cedalo ensures that users can easily connect to cloud and server systems, allowing for the orchestration of complex processes and the handling of high usage loads.

Exciva

Series A in 2021
Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing treatments for dementia and other neurological conditions. The company specializes in a targeted drug rescue program aimed at repurposing approved medications for new therapeutic indications. Exciva's approach includes the creation of symptomatic and disease-modifying therapies, alongside other formulations designed to address both neurological and psychological aspects of behavioral symptoms. By enabling the healthcare industry to access its innovative program, Exciva aims to improve treatment options and outcomes for patients suffering from various conditions, particularly those associated with dementia.

3YOURMIND

Series A in 2021
3YOURMIND GmbH, founded in 2013 and headquartered in Berlin, Germany, with additional offices in San Francisco and Wroclaw, develops an innovative software platform for industrial 3D printing. The company provides enterprise software that automates additive manufacturing processes, streamlining workflows for various industries. Its product suite encompasses tools for managing the entire additive manufacturing supply chain, from analyzing historical data to optimizing order management and production scheduling. By standardizing workflows and automating associated business processes, 3YOURMIND enables data-driven decision-making and supports agile manufacturing practices. Their solutions, including Agile PLM and Agile ERP, enhance product innovation and order tracking, while Agile MES improves transparency and information flow on the production floor. The company has successfully partnered with notable clients such as GKN, DB Schenker, and EOS, offering expert guidance throughout the additive manufacturing workflow, from concept to execution.

Actitrexx

Series A in 2021
ActiTrexx GmbH is a biotech start-up specializing in cellular therapy aimed at preventing inflammatory reactions associated with conditions such as graft-versus-host disease (GVHD), solid organ transplantation, and autoimmune diseases. The company's primary product, ATREGA, serves as a therapeutic option for patients who have undergone transplants, significantly enhancing survival rates. ActiTrexx focuses on developing and clinically testing cell therapeutics that help suppress transplant rejection and autoimmunity. By addressing the critical challenges of transplant rejection, the company's innovative therapies not only aim to improve patient survival but also enhance their overall quality of life and expand treatment options available to them.

Code Intelligence

Series A in 2020
Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in security software aimed at helping developers identify and address vulnerabilities in their code. The company offers an automated application security testing platform that utilizes coverage-based fuzzing and symbolic code execution to generate attack inputs, thereby facilitating the detection of critical vulnerabilities and crashes. This solution significantly reduces the need for extensive expert knowledge by establishing a continuous testing infrastructure. Code Intelligence serves a diverse clientele, including notable organizations such as Bosch, Deutsche Börse Group, and Deutsche Telekom, ensuring that their software remains secure and reliable.

Teralytics

Series D in 2019
Teralytics is a company specializing in mobility analytics, providing deep insights into human mobility needs through the use of big data and advanced machine learning. The company's platform is designed to optimize transportation planning and operations, helping clients address significant mobility challenges. Teralytics aims to transform how journeys are planned and managed, focusing on improving journey times, ensuring accessibility, enhancing operational efficiencies, and minimizing environmental impact. By delivering actionable insights, Teralytics supports the development of sustainable mobility solutions that cater to the needs of individuals and communities both now and in the future.

tado°

Secondary Market in 2018
tado° GmbH is a technology company based in Munich, Germany, with an additional office in London, United Kingdom. Founded in 2010, it specializes in developing and marketing innovative home climate control systems that enhance the efficiency of heating and cooling in residential and small business environments. The company's products integrate a hardware-software combination that leverages real-time data on resident behavior, weather forecasts, and building characteristics to optimize climate management. tado° sells its solutions through both retail outlets and online platforms, effectively bringing Internet of Things technology to the cleantech market.

Acousia Therapeutics

Series B in 2018
Acousia Therapeutics GmbH is a biotech company based in Tübingen, Germany, founded in 2012. It focuses on developing small molecule drugs aimed at treating hearing loss through local application. The company's innovative approach targets the regeneration of sensory hair cells in the inner ear, which are essential for hearing. By stimulating cellular regeneration from supporting cells, Acousia's therapies aim to restore hearing in patients affected by various conditions, including noise trauma, ototoxic drug treatment, and sudden deafness. Additionally, its research and development efforts are directed towards addressing age-related hearing decline.

otego

Seed Round in 2018
otego GmbH, founded in 2016 and headquartered in Karlsruhe, Germany, specializes in the development of thermoelectric generators (TEGs) that convert heat into electric power. These generators provide independent energy supplies for wireless sensors and actuators, making them suitable for various applications, including the Internet of Things, waste heat recovery, and Industry 4.0. The company emerged as a spin-off from the Karlsruhe Institute of Technology, founded by a diverse team of professionals, including physicians, a chemist, and a business engineer. This interdisciplinary collaboration is aimed at commercializing their innovative technology.

Crealytics

Series C in 2017
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

Amcure

Series B in 2016
amcure GmbH is a clinical-stage biopharmaceutical company based in Eggenstein-Leopoldshafen, Germany, focused on the research and development of peptide-based compounds designed to treat highly metastatic forms of squamous cancer. Founded in 2011 as a spin-off from the Karlsruhe Institute of Technology, amcure is dedicated to targeting the tumor-specific co-receptor CD44v6, which plays a critical role in activating various receptor tyrosine kinase pathways. Their lead candidate, AM001, effectively inhibits pathways associated with vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), providing a novel therapeutic approach to combat metastatic tumors. The company has advanced its first-in-class CD44v6 inhibitor, AMC303, into clinical development for solid tumors as of late 2016, aiming to improve treatment options for cancers such as pancreatic, head and neck, gastric, colorectal, breast, and lung cancer.

CorTec

Series B in 2016
CorTec is a developer and manufacturer focused on creating advanced medical devices for neuromodulation and brain-computer interfaces. The company has spent a decade on research and development, culminating in the innovative CorTec Brain Interchange™ System. This unique platform allows researchers and clinicians to devise novel therapies for neurological disorders. Central to this system are the °AirRay™ electrode arrays, which are laser-structured, soft, and flexible, ensuring a gentle fit to the brain's contours for reliable, permanent recordings. The implanted electronics, protected by biocompatible ceramic encapsulation, preprocess data and include a custom microchip developed with the University of Ulm. This microchip amplifies and digitizes neuronal signals across multiple channels, while eliminating the need for battery replacements through an external inductive power supply. Furthermore, CorTec provides additional support, services, and components related to the Brain Interchange System to Medtech companies and startups in the neurotechnology sector.

Enoware

Seed Round in 2015
Enoware specializes in wireless, miniaturized geothermal measuring capsules that enhance the efficiency and quality of geothermal probes. The company offers mobile sensor systems designed for fluid environments, providing users with access to crucial environmental information. By leveraging an online portal and smartphone application, Enoware facilitates system monitoring, optimization, and operational safety for geothermal energy applications. With a growing market in Germany, where over 300,000 geothermal probes are in use and 20,000 new systems are installed annually, Enoware aims to expand its customer base and enhance the capabilities of geothermal energy systems.

Biametrics

Series A in 2015
Biametrics specializes in providing innovative research and development services aimed at the academia, pharmaceutical, biotechnology, and diagnostic markets. The company's products focus on label-free detection systems that characterize biomolecular interactions, offering valuable kinetic and thermodynamic data, including affinity measurements and specificity information. Biametrics' technology enables enhanced data evaluation for applications in diagnostics and process analytics, allowing clients to gain insights into biomolecular behavior with unmatched performance in throughput and versatility.

Amcure

Series A in 2014
amcure GmbH is a clinical-stage biopharmaceutical company based in Eggenstein-Leopoldshafen, Germany, focused on the research and development of peptide-based compounds designed to treat highly metastatic forms of squamous cancer. Founded in 2011 as a spin-off from the Karlsruhe Institute of Technology, amcure is dedicated to targeting the tumor-specific co-receptor CD44v6, which plays a critical role in activating various receptor tyrosine kinase pathways. Their lead candidate, AM001, effectively inhibits pathways associated with vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), providing a novel therapeutic approach to combat metastatic tumors. The company has advanced its first-in-class CD44v6 inhibitor, AMC303, into clinical development for solid tumors as of late 2016, aiming to improve treatment options for cancers such as pancreatic, head and neck, gastric, colorectal, breast, and lung cancer.

Crealytics

Series B in 2014
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

PressMatrix

Series A in 2013
PressMatrix GmbH, founded in 2009 and headquartered in Berlin, Germany, specializes in digital publishing services tailored for magazines, customer documents, articles, books, journals, and catalogs. The company provides a comprehensive publishing solution that includes subscription models, a Workbench application, and mobile app development. It aims to assist publishers, agencies, and enterprises in effectively delivering their content across various platforms, particularly on tablets and mobile devices. PressMatrix's notable clientele includes Georg Thieme Verlag, Carry-On Publishing GmbH, and New Business Verlag GmbH & Co. KG. Originally established as bblabs UG, the company rebranded to PressMatrix GmbH in January 2011, reinforcing its commitment to advancing digital publishing technologies.

Crealytics

Venture Round in 2013
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

Tocario

Seed Round in 2012
Tocario GmbH is a cloud IT company based in Stuttgart, Germany, founded in 2011. It specializes in developing a hosted virtual desktop solution that provides an automated, self-service platform for IT professionals to manage desktop infrastructure from a single interface. Tocario offers one of the few fully automated Desktop-as-a-Service (DaaS) platforms, catering to European end customers and white-label partners, as well as providing enterprise licenses to cloud service providers. The platform addresses various business needs by enhancing agility and reducing complexity, allowing for the simple and secure deployment of virtual desktop workplaces across different devices without software or operating system limitations. Tocario's technology is available as a service, enabling customers to benefit from cloud flexibility without upfront investments. The company has established partnerships with major technology firms and has received recognition for its innovative approach to digital workspaces.

avandeo

Venture Round in 2012
avandeo, a Munich, Germany- and Shanghai, China-based startup that operates an online destination for designer furniture and home accessories.

CargoGuard

Venture Round in 2011
CargoGuard GmbH is a German company specializing in security and transparency solutions for logistics. Founded in 2007 and based in Merseburg, it offers a range of services including portable tracking, secure monitoring of valuables, fixed tracking, and Internet-of-Things lock solutions. The company's innovative system is designed to protect valuable goods, high-end products, and sensitive documents from risks such as loss, theft, and manipulation during transportation and storage. By integrating locking and sealing functions, GPS tracking, condition monitoring, and emergency response features, CargoGuard enables logistics companies, manufacturers, and authorities to effectively manage and safeguard their valuable assets throughout the intermodal supply chain. Its solutions cater to various sectors, including cash and valuables transportation, logistics, automotive, insurance, and manufacturing.

Crealytics

Venture Round in 2011
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

Intelligent Fluid

Series B in 2011
Intelligent Fluids GmbH is a technology company specializing in the development of innovative, high-performance cleaning fluids that utilize a patented technology combining gentle ingredients to create dynamic phase fluids. These fluids are designed for specific applications and function effectively without chemical dissolving or etching, making them safe for users, equipment, and the environment. They are particularly suited for industries such as microelectronics, industrial maintenance, optics, printing, and building protection, among others. The company's products facilitate the removal of dirt, residues, coatings, and lacquers, offering significant advantages in process optimization and cost savings. Additionally, Intelligent Fluids is committed to sustainability, supporting multiple UN Sustainable Development Goals by reducing carbon emissions, energy consumption, and material use. Beyond its product line, the company also engages in joint development and private label agreements, further broadening its impact in the eco-friendly cleaning sector.

Phenex Pharmaceuticals

Series C in 2010
Phenex Pharmaceuticals AG is a drug discovery and development company founded in 2002 and headquartered in Ludwigshafen, Germany, with additional laboratories and offices in Heidelberg. The company specializes in small-molecule drug discovery, focusing on nuclear receptors to address various disease areas, including liver diseases, intestinal diseases, and cancer. Current research includes developing RORγt inverse agonists for autoimmune diseases and FXR agonists for non-alcoholic steatohepatitis. Phenex is dedicated to not only creating therapeutics for established targets but also identifying novel molecular mechanisms, which has led to the development of proprietary therapeutic small molecules. The company operates within the Biotech Cluster Rhine-Neckar, leveraging its expertise in biology and chemistry to advance innovative treatment options.

MTM Laboratories

Series C in 2009
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.

Sloning BioTechnology

Venture Round in 2009
Sloning BioTechnology specializes in the synthesis of DNA molecules through its innovative and patented Slonomics technology platform. This platform enables the production of DNA with unique features, including enhanced sequence limitations, reliability, and cost-effectiveness, all achieved on an industrial scale using automated robotic systems. In addition to gene synthesis, Sloning BioTechnology offers a range of synthetic biology tools, positioning itself as a key player in the field of biotechnology.

Oxid eSales

Venture Round in 2008
OXID eSales AG, headquartered in Freiburg, Germany, specializes in multi-channel e-commerce solutions, offering open source shopping cart software known as OXID eShop. Founded in 2003, the company serves both business-to-business (B2B) and business-to-consumer (B2C) markets, providing scalable and customizable e-commerce platforms. Major clients such as Lekkerland, Strenesse, Intersport, Gravis, and Deutsche Post utilize OXID's solutions for their online operations. The platform is designed for flexibility and rapid deployment, supported by a network of over 100 certified solution partners. OXID eShop integrates with the OXID eFire intelligence platform, which facilitates cloud-based e-commerce management, including online marketing, payment services, and intelligent search functionalities. This commercial open source software approach ensures high-quality development and long-term investment security for users, making it a valuable choice for medium-sized companies seeking to enhance their digital sales processes.

Phenex Pharmaceuticals

Series B in 2008
Phenex Pharmaceuticals AG is a drug discovery and development company founded in 2002 and headquartered in Ludwigshafen, Germany, with additional laboratories and offices in Heidelberg. The company specializes in small-molecule drug discovery, focusing on nuclear receptors to address various disease areas, including liver diseases, intestinal diseases, and cancer. Current research includes developing RORγt inverse agonists for autoimmune diseases and FXR agonists for non-alcoholic steatohepatitis. Phenex is dedicated to not only creating therapeutics for established targets but also identifying novel molecular mechanisms, which has led to the development of proprietary therapeutic small molecules. The company operates within the Biotech Cluster Rhine-Neckar, leveraging its expertise in biology and chemistry to advance innovative treatment options.

Sloning BioTechnology

Series E in 2007
Sloning BioTechnology specializes in the synthesis of DNA molecules through its innovative and patented Slonomics technology platform. This platform enables the production of DNA with unique features, including enhanced sequence limitations, reliability, and cost-effectiveness, all achieved on an industrial scale using automated robotic systems. In addition to gene synthesis, Sloning BioTechnology offers a range of synthetic biology tools, positioning itself as a key player in the field of biotechnology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.